This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Erytech Pharma. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovative Contributions of Willy Berlier in Cancer Treatment
Introduction
Willy Berlier is a notable inventor based in Lyons, France, recognized for his significant contributions to cancer treatment methodologies. His innovative approach focuses on the depletion of specific amino acids to combat various forms of cancer in mammals, including humans.
Latest Patents
Willy Berlier holds a patent for a method of treating a mammal against cancer using methionine and asparagine depletion. This invention introduces a novel technique for addressing both liquid and solid cancers by administering methioninase prior to asparaginase. The patent also covers dietary methionine deprivation, which may be combined with methioninase administration before asparaginase treatment. The methods described in the patent allow for the use of methioninase and asparaginase in free form, pegylated form, or encapsulated into erythrocytes.
Career Highlights
Berlier is associated with Erytech Pharma, a company dedicated to developing innovative treatments for cancer. His work at Erytech Pharma has positioned him as a key player in the field of cancer research and treatment.
Collaborations
Willy Berlier collaborates with talented professionals such as Karine Aguera and Fabien Gay, contributing to a dynamic research environment focused on advancing cancer therapies.
Conclusion
Willy Berlier's innovative methods for cancer treatment highlight the potential of amino acid depletion in therapeutic applications. His contributions continue to influence the landscape of cancer research and treatment methodologies.